Insider Trading Alert - ITMN, M And ILMN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 11, 2014, 134 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $363.00 to $110,557,762.60.

Highlighted Stocks Traded by Insiders:

InterMune (ITMN) - FREE Research Report

Leff Jonathan A who is EVP of R&D at InterMune sold 748 shares at $31.75 on March 11, 2014. Following this transaction, the EVP of R&D owned 45,879 shares meaning that the stake was reduced by 1.6% with the 748-share transaction.

The shares most recently traded at $33.64, up $1.89, or 5.62% since the insider transaction. Historical insider transactions for InterMune go as follows:

  • 4-Week # shares sold: 138,646
  • 12-Week # shares sold: 258,646
  • 24-Week # shares sold: 298,646

The average volume for InterMune has been 2.7 million shares per day over the past 30 days. InterMune has a market cap of $2.7 billion and is part of the health care sector and drugs industry. Shares are up 107.6% year-to-date as of the close of trading on Friday.

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. Currently there are 8 analysts that rate InterMune a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITMN - FREE

TheStreet Quant Ratings rates InterMune as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally high debt management risk. Get the full InterMune Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Macy's (M) - FREE Research Report

Broderick Dennis J who is EVP, Gen.Counsel & Secretary at Macy's sold 17,906 shares at $57.87 on March 11, 2014. Following this transaction, the EVP, Gen.Counsel & Secretary owned 21,397 shares meaning that the stake was reduced by 45.56% with the 17,906-share transaction.

The shares most recently traded at $58.13, up $0.26, or 0.44% since the insider transaction. Historical insider transactions for Macy's go as follows:

  • 4-Week # shares sold: 284,753
  • 12-Week # shares sold: 284,753
  • 24-Week # shares sold: 294,753

The average volume for Macy's has been 4.0 million shares per day over the past 30 days. Macy's has a market cap of $21.1 billion and is part of the services sector and retail industry. Shares are up 7.3% year-to-date as of the close of trading on Friday.

Macy's, Inc., together with its subsidiaries, operates stores and Internet Websites in the United States. The stock currently has a dividend yield of 1.75%. The company has a P/E ratio of 14.3. Currently there are 9 analysts that rate Macy's a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on M - FREE

TheStreet Quant Ratings rates Macy's as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Macy's Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Illumina (ILMN) - FREE Research Report

Bouchard Michel who is Chief Accounting Officer at Illumina sold 2,168 shares at $167.21 on March 11, 2014. Following this transaction, the Chief Accounting Officer owned 25,049 shares meaning that the stake was reduced by 7.97% with the 2,168-share transaction.

The shares most recently traded at $166.55, down $0.66, or 0.4% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 1,780
  • 12-Week # shares sold: 14,664
  • 24-Week # shares sold: 39,664

The average volume for Illumina has been 1.9 million shares per day over the past 30 days. Illumina has a market cap of $22.0 billion and is part of the health care sector and drugs industry. Shares are up 54.96% year-to-date as of the close of trading on Friday.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 190.4. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000